ArticleJournal of fluorescence2025
Development of a Peptide Aptamer-Based TRFIA for the Quantitive Detection of SARS-CoV-2 Nucleocapsid Protein.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peptide Aptamers: Innovative Design and Applications in Pathogen Detection.Chembiochem : a European journal of chemical biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study, we employed computer-aided design to develop 27 peptide aptamers, and initially screened 11 candidates with binding energies less than - 6.0 kcal/mol. Subsequently, three peptide aptamers with strong specificity were selected using a direct time-resolved fluorescence immunoassay (TRFIA). Peptide aptamer B3, in combination with monoclonal antibody R001, was used to construct a TRFIA-based sandwich assay system. The performance of this system was evaluated concerning sensitivity, specificity, and reproducibility, and was further tested using 20 simulated pharyngeal swab samples. The dominant peptide aptamer, B3(RGQGVPI), was identified as the most promising candidate. This peptide demonstrated high specificity for the SARS-CoV-2 nucleocapsid (N) protein, with the lowest detectable concentration of 203.78 pg/mL. Importantly, the peptide had no cross-reactions with other potential interferents, including RSV, Flu A, and MP, confirming its specificity. The assay also exhibited good reproducibility, with coefficients of variation of 11.33% and 8.00% at different concentrations in pharyngeal swab samples. Additionally, the LOB and LOD in clinical samples were 31.59 pg/mL and 243.70 pg/mL and the correlation coefficient R
Indexed as
Identifiers
39985615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.